El-Achkar Adnan, Souhami Luis, Kassouf Wassim
Experimental surgery, McGill University Health Center, 1001 Decarie Blvd, Montreal, QC, H4A 3J1, Canada.
Department of Radiation Oncology, McGill University Health Center, 1001 Decarie Blvd, Montreal, QC, H4A 3J1, Canada.
Curr Urol Rep. 2018 Nov 3;19(12):108. doi: 10.1007/s11934-018-0859-z.
This review targets the latest literature on bladder preservation therapy with emphasis on trimodal therapy (TMT), highlighting its role in the management of muscle invasive bladder cancer (MIBC) and outlining future directions in bladder preservation research.
TMT is the most promising bladder preservation treatment modality. Comparable results to contemporary radical cystectomy series are seen in properly selected patients. A multidisciplinary team approach is critical in the management of these patients. Future research is directed at the integration of immunotherapy into the treatment protocol. TMT, involving maximal transurethral resection followed by chemoradiation, is an attractive alternative to radical cystectomy with urinary diversion in carefully selected patients with muscle invasive disease. In the absence of randomized trial (RCT), comparison between TMT and cystectomy, based on retrospective data from large centers, suggests comparable oncological outcomes, with a favorable impact on quality of life.
本综述聚焦于膀胱保留治疗的最新文献,重点关注三联疗法(TMT),强调其在肌肉浸润性膀胱癌(MIBC)管理中的作用,并概述膀胱保留研究的未来方向。
TMT是最具前景的膀胱保留治疗方式。在经过适当选择的患者中,可观察到与当代根治性膀胱切除术系列相当的结果。多学科团队方法在这些患者的管理中至关重要。未来研究方向是将免疫疗法纳入治疗方案。TMT包括最大程度的经尿道切除术,随后进行放化疗,对于精心挑选的肌肉浸润性疾病患者而言,是根治性膀胱切除术加尿流改道的一种有吸引力的替代方案。在缺乏随机试验(RCT)的情况下,基于大型中心的回顾性数据对TMT和膀胱切除术进行比较,结果显示肿瘤学结局相当,且对生活质量有积极影响。